Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210259/S-006; 210259/S-007 Part 16, page:21 PDF 7375k",https://www.pharmapendium.com/browse/fda/Acalabrutinib/efa223c1346a408063449cedd71ec87a?reference=21,2019.0,CC#CC(=O)N1CCC[CH]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Hepatitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:13 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=13,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Hepatitis,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/485/II/30, page:9 PDF 116k",https://www.pharmapendium.com/browse/ema/Adefovir Dipivoxil/05d8eb51641806e5c5daf0470d4cdae0?reference=9,2008.0,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:3 PDF 274k",https://www.pharmapendium.com/browse/ema/Agomelatine/b52c4999c51accf6b1679047c049acb6?reference=3,2020.0,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
Albendazole,CCCSC1=CC2=C(NC(NC(=O)OC)=N2)C=C1,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical Officer Review 020666 Part 02, page:5 PDF 1644k",https://www.pharmapendium.com/browse/fda/Albendazole/717289ccbfffabc58f7eddfcc3e18e38?reference=5,1996.0,CCCSC1=CC2=C(NC(NC(=O)OC)=N2)C=C1
Alosetron Hydrochloride,CN1C2=C(C(=O)N(CC2)CC2=C(C)NC=N2)C2=C1C=CC=C2,Hepatitis,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Label 021107/S-012, page:11 PDF 406k",https://www.pharmapendium.com/browse/fda/Alosetron Hydrochloride/6f5d6f111fe5cba6084deda6eb278cbe?reference=11,2005.0,CN1C2=C(C(=O)N(CC2)CC2=C(C)NC=N2)C2=C1C=CC=C2
Alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,Hepatitis,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Printed Labeling 021726/S-000, page:19 PDF 1977k",https://www.pharmapendium.com/browse/fda/Alprazolam/1df31e0b37180d1cffaefc2ea15e6eca?reference=19,,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022081/S-000 Part 01, page:64 PDF 5894k",https://www.pharmapendium.com/browse/fda/Ambrisentan/e117720ab3e6f9b3a0d7516463fe958e?reference=64,2007.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Amdinocillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2\N=C\N1CCCCCC1)C(O)=O,Hepatitis,Human,-1.7781512503836436,Repeated,Intravenous,"FDA approval package document: Approval Package 050565 Part 03, page:26 PDF 5467k",https://www.pharmapendium.com/browse/fda/Amdinocillin/3a672ae67c0f203e38e26f2475b5620c?reference=26,1983.0,[H][C]12SC(C)(C)[CH](N1C(=O)[CH]2\N=C\N1CCCCCC1)C(O)=O
Amineptine,OC(=O)CCCCCCNC1C2=CC=CC=C2CCC2=CC=CC=C12,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Amineptine10v84n1   ---   DOI:10.1590/S0365-05962009000100010   JOURNAL:Anais Brasileiros de Dermatologia   PAGES:71   VOLUME:84,http://dx.doi.org/10.1590/S0365-05962009000100010,2009.0,OC(=O)CCCCCCNC1C2=CC=CC=C2CCC2=CC=CC=C12
Aminosalicylic Acid,NC1=CC=C(C(O)=O)C(O)=C1,Hepatitis,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 006924, page:5 PDF 675k",https://www.pharmapendium.com/browse/fda/Aminosalicylic Acid/0e570efeadba8d5ab058994c07b64375?reference=5,,NC1=CC=C(C(O)=O)C(O)=C1
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatitis,Human,-1.380211241711606,Repeated,Intravenous,"FDA approval package document: Label 022325/S-000, page:9 PDF 1417k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/c0699c2ee28215284fc348c87712e2da?reference=9,2009.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Amoxapine,ClC1=CC=C2OC3=CC=CC=C3N=C(N3CCNCC3)C2=C1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 018021/S-017, S-001, S-002 Part 01, page:24 PDF 4009k",https://www.pharmapendium.com/browse/fda/Amoxapine/7bba0ed590fbda2ff00439218823d503?reference=24,1976.0,ClC1=CC=C2OC3=CC=CC=C3N=C(N3CCNCC3)C2=C1
Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,Hepatitis,Human,0.0,Repeated,Intravenous,"FDA approval package document: Approval Package 050724 Part 01, page:8 PDF 6223k",https://www.pharmapendium.com/browse/fda/Amphotericin B/d0bf86ad757877fb6802e13c91e66f48?reference=8,1995.0,[H][C]12C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH](C)[CH](C)OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C](O)(C[CH](O)[CH]1C(O)=O)O2
Anagrelide Hydrochloride,ClC1=C(Cl)C2=C(C=C1)N=C1NC(=O)CN1C2,Hepatitis,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:27 PDF 317k",https://www.pharmapendium.com/browse/ema/Anagrelide Hydrochloride/17adf620f2a256a476ef21cdd46f94dc?reference=27,2020.0,ClC1=C(Cl)C2=C(C=C1)N=C1NC(=O)CN1C2
Anastrozole,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,Hepatitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Label 022214/S-000, page:13 PDF 2087k",https://www.pharmapendium.com/browse/fda/Anastrozole/4b1505ca54408c397cb138821e893513?reference=13,2008.0,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatitis,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: ANNEX I, page:4 PDF 246k",https://www.pharmapendium.com/browse/ema/Anidulafungin/b0126dc536ecaaa2fca7659f1a5064c5?reference=4,2020.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/478338/2014; EMEA/H/C/002148/II/0014/G, page:82 PDF 2588k",https://www.pharmapendium.com/browse/ema/Apixaban/63204c7b176325279d63eef03f2d71ff?reference=82,2014.0,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Hepatitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Printed Labeling 021713/S-000, page:32 PDF 2370k",https://www.pharmapendium.com/browse/fda/Aripiprazole/244853cd02a9a87a16838c41b74aa6e6?reference=32,2004.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Armodafinil,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021875/S-000 Part 01, page:52 PDF 5290k",https://www.pharmapendium.com/browse/fda/Armodafinil/460706a7575b611d14fb010477cae2ac?reference=52,2007.0,NC(=O)C[S](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019402/S-001, S-003, S-004, S-007, S-010 Part 07, page:4 PDF 908k",https://www.pharmapendium.com/browse/fda/Astemizole/75eb412b8df9924bb04235b2e6fc039e?reference=4,1988.0,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1
Atorvastatin Calcium,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020702/S-039, page:24 PDF 10121k",https://www.pharmapendium.com/browse/fda/Atorvastatin Calcium/e67622e3ceec2520b09109dab70889de?reference=24,2004.0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[CH](O)C[CH](O)CC([O-])=O)C1=CC=C(F)C=C1
Atovaquone,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=C(C=CC=C2)C1=O,Hepatitis,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020500/S-005; 020505/S-005 Part 04, page:1 PDF 653k",https://www.pharmapendium.com/browse/fda/Atovaquone/49ef6f013253d56476c54071c518c556?reference=1,1998.0,OC1=C([CH]2CC[CH](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=C(C=CC=C2)C1=O
Azapropazone,CCCC1C(=O)N2N(C1=O)C1=C(C=CC(C)=C1)N=C2N(C)C,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Azapropazone64c   ---   JOURNAL:British Medical Journal   PAGES:1614   VOLUME:297,,1988.0,CCCC1C(=O)N2N(C1=O)C1=C(C=CC(C)=C1)N=C2N(C)C
Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Hepatitis,Human,-2.6989700043360187,Repeated,Oral/intravenous,"FDA approval package document: Label 050809/S-000, page:15 PDF 1584k",https://www.pharmapendium.com/browse/fda/Azithromycin/0c2ef5a844f20b7e1b10400ba21520ef?reference=15,2006.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)CN(C)[CH](C)[CH](O)[C]1(C)O
Aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O,Hepatitis,Human,-3.4771212547196626,Repeated,Parenteral,"FDA approval package document: Approval Package 050580 Part 01, page:28 PDF 8962k",https://www.pharmapendium.com/browse/fda/Aztreonam/6c273762992adaf8c1f986d26d8f0572?reference=28,1986.0,C[CH]1[CH](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
Benoxaprofen,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018250 Part 06, page:37 PDF 6047k",https://www.pharmapendium.com/browse/fda/Benoxaprofen/5312b25dcc6727268d88955af8b474b5?reference=37,1976.0,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1
Benznidazole,O=C(CN1C=CN=C1N(=O)=O)NCC1=CC=CC=C1,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209570/S-000 Part 11, page:23 PDF 812k",https://www.pharmapendium.com/browse/fda/Benznidazole/e20dfb23182e24162b563c91b17106a2?reference=23,2017.0,O=C(CN1C=CN=C1N(=O)=O)NCC1=CC=CC=C1
Bepridil Hydrochloride,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019002 Part 02, page:22 PDF 5831k",https://www.pharmapendium.com/browse/fda/Bepridil Hydrochloride/012c26186da387701d74d5aa3279e988?reference=22,1990.0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F,Hepatitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical Officer Review 020498, page:3 PDF 255k",https://www.pharmapendium.com/browse/fda/Bicalutamide/27f03ce3355ae660a0da79fc9524871a?reference=3,1995.0,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F
Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,Hepatitis,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 437k",https://www.pharmapendium.com/browse/ema/Bosentan/f158ae595a2fc0654d2fbc1990ad2869?reference=11,2020.0,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1
Bosutinib Monohydrate,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/70979/2013, page:69 PDF 1136k",https://www.pharmapendium.com/browse/ema/Bosutinib Monohydrate/ab40610c3303b50455387aeda860af0b?reference=69,2013.0,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
Bumetanide,CCCCNC1=CC(=CC(=C1OC1=CC=CC=C1)S(N)(=O)=O)C(O)=O,Hepatitis,Human,-1.4471580313422192,Repeated,Oral/intravenous,"FDA approval package document: Approval Package 018225/S-009, S-002; 018226/S-002 Part 02, page:41 PDF 6224k",https://www.pharmapendium.com/browse/fda/Bumetanide/52a32cff72a31c3a1e345079cd7f9bd7?reference=41,1981.0,CCCCNC1=CC(=CC(=C1OC1=CC=CC=C1)S(N)(=O)=O)C(O)=O
Buprenorphine Hydrochloride,[H][C@@]1(C[C@@]23CC[C@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Hepatitis,Human,-1.2041199826559248,Repeated,Sublingual,"FDA approval package document: Medical/Clinical Review 204442/S-000 Part 02, page:97 PDF 17649k",https://www.pharmapendium.com/browse/fda/Buprenorphine Hydrochloride/832f0ccf37dcc98c3672cd9af38e1a97?reference=97,2013.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Bupropion Hydrochloride,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 077285/S-000, page:3 PDF 1335k",https://www.pharmapendium.com/browse/fda/Bupropion Hydrochloride/d6dd095cbc079a81613951fe291c22c1?reference=3,2008.0,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Hepatitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Review 212887/S-000; 212888/S-000 Part 19, page:9 PDF 701k",https://www.pharmapendium.com/browse/fda/Cabotegravir Sodium/d8a48ae1e91b38d344fc32218cf5483b?reference=9,2019.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
"Calcitonin, Salmon",CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O,Hepatitis,Human,-2.3010299956639813,Repeated,Intranasal,"FDA approval package document: Approval Package 076396/S-000 Part 01, page:10 PDF 3504k","https://www.pharmapendium.com/browse/fda/Calcitonin, Salmon/54adf4b8f4223a5bfe57dca6cca09bba?reference=10",2008.0,CC(C)C[CH](NC(=O)[CH](NC(=O)[CH]1CSSC[CH](N)C(=O)N[CH](CO)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CO)C(=O)N[CH]([CH](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[CH](CCCCN)C(=O)N[CH](CC(C)C)C(=O)N[CH](CO)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC1=CN=CN1)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(N)=O)C(=O)N[CH]([CH](C)O)C(=O)N[CH](CC1=CC=C(O)C=C1)C(=O)N1CCC[CH]1C(=O)N[CH](CCCNC(N)=N)C(=O)N[CH]([CH](C)O)C(=O)N[CH](CC(N)=O)C(=O)N[CH]([CH](C)O)C(=O)NCC(=O)N[CH](CO)C(=O)NCC(=O)N[CH]([CH](C)O)C(=O)N1CCC[CH]1C(N)=O
Calcium 4-Benzamidosalicylate,OC1=CC(NC(=O)C2=CC=CC=C2)=CC=C1C([O-])=O,Hepatitis,Human,-4.176091259055681,Repeated,Oral,"FDA approval package document: Review 012310, page:5 PDF 1140k",https://www.pharmapendium.com/browse/fda/Calcium 4-Benzamidosalicylate/84621efd8ca38d6d96f0129155e39eb0?reference=5,,OC1=CC(NC(=O)C2=CC=CC=C2)=CC=C1C([O-])=O
Calcium Aminosalicylate,NC1=CC=C(C([O-])=O)C(O)=C1,Hepatitis,Human,-4.176091259055681,Repeated,Oral,"FDA approval package document: Approval Package 008462, page:4 PDF 1056k",https://www.pharmapendium.com/browse/fda/Calcium Aminosalicylate/7f4a7d168b671837d5466c0fee444c30?reference=4,1957.0,NC1=CC=C(C([O-])=O)C(O)=C1
Candesartan Cilexetil,CCOC1=NC2=CC=CC(C(=O)OC(C)OC(=O)OC3CCCCC3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Hepatitis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020838/S-000 Part 04, page:38 PDF 1288k",https://www.pharmapendium.com/browse/fda/Candesartan Cilexetil/a3d1fecf09a1569ba1bad6983f1451a3?reference=38,1998.0,CCOC1=NC2=CC=CC(C(=O)OC(C)OC(=O)OC3CCCCC3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Cannabidiol,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 210365/S-000 Part 02, page:153 PDF 20990k",https://www.pharmapendium.com/browse/fda/Cannabidiol/6299ed807f77fbf5b95d4a503ff58399?reference=153,2018.0,CCCCCC1=CC(O)=C([CH]2C=C(C)CC[CH]2C(C)=C)C(O)=C1
Capmatinib Hydrochloride,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 213591/S-000 Part 09, page:19 PDF 1046k",https://www.pharmapendium.com/browse/fda/Capmatinib Hydrochloride/eab6c5d203e9be4cefc241fe3fad3c0a?reference=19,2020.0,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1
Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,Hepatitis,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 018281/S-031, page:16 PDF 2105k",https://www.pharmapendium.com/browse/fda/Carbamazepine/ce26ebd213d85fb7fb3989af05f689a3?reference=16,2001.0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Cariprazine Hydrochloride,CN(C)C(=O)N[C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl,Hepatitis,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204370/S-000 Part 09, page:19 PDF 4381k",https://www.pharmapendium.com/browse/fda/Cariprazine Hydrochloride/28ade9a21395214a85a4a9978b121cc7?reference=19,2013.0,CN(C)C(=O)N[CH]1CC[CH](CC1)CCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl
Carteolol Hydrochloride,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019204 Part 01, page:31 PDF 5749k",https://www.pharmapendium.com/browse/fda/Carteolol Hydrochloride/7500040fe3a502b3c82f20206fa1b9cb?reference=31,1988.0,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2
Cefaclor,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,Hepatitis,Human,-3.0,Repeated,Oral,"FDA approval package document: FDA Approval Document 050673 Part 01, page:81 PDF 2224k",https://www.pharmapendium.com/browse/fda/Cefaclor/dce2f0f5a6fda796b654c80c296791ac?reference=81,1993.0,N[CH](C(=O)N[CH]1[CH]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Hepatitis,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050749/S-000 Part 03, page:75 PDF 3222k",https://www.pharmapendium.com/browse/fda/Cefdinir/212ed378c202b7d2419ca84211634faa?reference=75,1996.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Cefixime,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 202091/S-000, page:9 PDF 665k",https://www.pharmapendium.com/browse/fda/Cefixime/3eaea45d1095013613fdc23b10a629cd?reference=9,2013.0,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[CH]1[CH]2SCC(C=C)=C(N2C1=O)C(O)=O
Ceforanide,NCC1=CC=CC=C1CC(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CC(O)=O)=C(N2C1=O)C(O)=O,Hepatitis,Human,-3.6020599913279625,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: Ceforanide0056   ---   DOI:10.1128/AAC.19.2.256   JOURNAL:Antimicrobial Agents and Chemotherapy   PAGES:256   VOLUME:19,http://dx.doi.org/10.1128/AAC.19.2.256,1981.0,NCC1=CC=CC=C1CC(=O)N[CH]1[CH]2SCC(CSC3=NN=NN3CC(O)=O)=C(N2C1=O)C(O)=O
Ceftibuten Dihydrate,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical Officer Review 050685 Part 03, page:36 PDF 1515k",https://www.pharmapendium.com/browse/fda/Ceftibuten Dihydrate/befaead5a22d932d4a1e075db3e151cf?reference=36,1993.0,[H][C]12SCC=C(N1C(=O)[CH]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Scientific Discussion, page:24 PDF 583k",https://www.pharmapendium.com/browse/ema/Celecoxib/1f5e6bf541894676bfe0563f98510cba?reference=24,2005.0,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Hepatitis,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/170114/2015; EMEA/H/C/003819/0000, page:86 PDF 3461k",https://www.pharmapendium.com/browse/ema/Ceritinib/625fcc14a77690a19eb6362758b85c7e?reference=86,2015.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Cerivastatin Sodium,COCC1=C(N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1)C(C)C,Hepatitis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Label 020740/S-019, page:11 PDF 353k",https://www.pharmapendium.com/browse/fda/Cerivastatin Sodium/d5628c459b1745bc3c9b5651c52f7c7a?reference=11,2002.0,COCC1=C(N=C(C(C)C)C(\C=C\[CH](O)C[CH](O)CC([O-])=O)=C1C1=CC=C(F)C=C1)C(C)C
Cetirizine Hydrochloride,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022155/S-000 Part 01, page:43 PDF 7190k",https://www.pharmapendium.com/browse/fda/Cetirizine Hydrochloride/5477eee343e2d9bd7ae6807c4260c83f?reference=43,2007.0,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Chlorpromazine Hydrochloride,CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Chlorpromazine0041a   ---   JOURNAL:British Medical Journal   PAGES:579   VOLUME:2,,1954.0,CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Hepatitis,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020780/S-017, S-018; 019537/S-053, S-054, page:24 PDF 3215k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/0e2c9703e8f743bf0652849a2b661fe1?reference=24,2004.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Cisapride Monohydrate,CO[C@@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020398 020210/S-001, S-007 Part 01, page:20 PDF 6302k",https://www.pharmapendium.com/browse/fda/Cisapride Monohydrate/9f79826e78993b1e1337272a6de6e932?reference=20,1995.0,CO[CH]1CN(CCCOC2=CC=C(F)C=C2)CC[CH]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
Citalopram Hydrobromide,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020822/S-042; 021046/S-019 Part 02, page:26 PDF 436k",https://www.pharmapendium.com/browse/fda/Citalopram Hydrobromide/4b374a2e2e10917b9d0839e1502121b5?reference=26,2012.0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 11, page:1 PDF 23631k",https://www.pharmapendium.com/browse/fda/Cladribine/cdf7c590901bed412a0ba7bd776ef517?reference=1,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical Officer Review 050775, page:18 PDF 1371k",https://www.pharmapendium.com/browse/fda/Clarithromycin/503219ac0311bbd3494effa9290c315a?reference=18,2000.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(C[CH](C)C(=O)[CH](C)[CH](O)[C]1(C)O)OC
Clofazimine,CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C/1NC1=CC=C(Cl)C=C1,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 019500/S-000, page:14 PDF 2175k",https://www.pharmapendium.com/browse/fda/Clofazimine/698747737f2e7d99da9cfa67f709a871?reference=14,1985.0,CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C/1NC1=CC=C(Cl)C=C1
Clomipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12,Hepatitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019906/S-022, page:7 PDF 1806k",https://www.pharmapendium.com/browse/fda/Clomipramine Hydrochloride/05cd449a93ff3f50452808a03b34d55e?reference=7,1999.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12
Clonidine,ClC1=CC=CC(Cl)=C1NC1=NCCN1,Hepatitis,Human,-1.7160033436347992,Repeated,Oral,"FDA approval package document: Label 022500/S-000, page:3 PDF 624k",https://www.pharmapendium.com/browse/fda/Clonidine/eb6bbc8baed087fad3e358a7f72df3c5?reference=3,,ClC1=CC=CC(Cl)=C1NC1=NCCN1
Clopidogrel Hydrobromide,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl,Hepatitis,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 770k",https://www.pharmapendium.com/browse/ema/Clopidogrel Hydrobromide/f4e3980f774689c09aa0d0a34c5849df?reference=9,2015.0,COC(=O)[CH](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl
Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 076387/S-000, page:20 PDF 4831k",https://www.pharmapendium.com/browse/fda/Clotrimazole/cef0ccd841fd1322d55de96d8415658d?reference=20,2002.0,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Hepatitis,Human,-2.6532125137753435,Repeated,Oral,"FDA approval package document: Review 019758/S-047, page:25 PDF 10755k",https://www.pharmapendium.com/browse/fda/Clozapine/074375bc33fa11cc8237082bf942999f?reference=25,2002.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,Hepatitis,Human,-1.9030899869919435,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 021697/S-000 Part 03, page:67 PDF 4991k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/011e8a458cc05207fd7bccbe97a4a265?reference=67,2005.0,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1
Crizotinib,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/497137/2012; EMEA/H/C/002489, page:63 PDF 1174k",https://www.pharmapendium.com/browse/ema/Crizotinib/03002030fc9de8da9d419fa9fadd0255?reference=63,2012.0,C[CH](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl
Cyclobenzaprine Hydrochloride,CN(C)CC\C=C1\C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Hepatitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021777/S-000, page:21 PDF 6375k",https://www.pharmapendium.com/browse/fda/Cyclobenzaprine Hydrochloride/d2cb881e69752f874659302be787c471?reference=21,2005.0,CN(C)CC\C=C1\C2=C(C=CC=C2)C=CC2=C1C=CC=C2
Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 203856/S-000, page:7 PDF 333k",https://www.pharmapendium.com/browse/fda/Cyclophosphamide/d134b6b0c0f1d60144f6d82dbd25f9e9?reference=7,2013.0,ClCCN(CCCl)P1(=O)NCCCO1
Dantrolene Sodium,[O-]C1=NC(=O)CN1\N=C\C1=CC=C(O1)C1=CC=C(C=C1)N(=O)=O,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 017443 Part 02, page:35 PDF 6916k",https://www.pharmapendium.com/browse/fda/Dantrolene Sodium/db9fce57c8951e87dfc4cada09b619b3?reference=35,1974.0,[O-]C1=NC(=O)CN1\N=C\C1=CC=C(O1)C1=CC=C(C=C1)N(=O)=O
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/664598/2014; EMEA/H/C/000707/II/0063, page:41 PDF 1469k",https://www.pharmapendium.com/browse/ema/Darunavir Ethanolate/37765f0cf3e035ae6035460e0832b61b?reference=41,2014.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Dasatinib,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1,Hepatitis,Human,-2.146128035678238,Repeated,Oral,"EMA approval document: ANNEX I, page:14 PDF 1664k",https://www.pharmapendium.com/browse/ema/Dasatinib/77004e26e51c3fd64afb4e0b6a644257?reference=14,2020.0,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021882/S-000 Part 02, page:31 PDF 5881k",https://www.pharmapendium.com/browse/fda/Deferasirox/0fee9c8dc7b2cc5ecf96f3dfdf7b823c?reference=31,2005.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Deferiprone,CN1C=CC(=O)C(O)=C1C,Hepatitis,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021825/S-000 Part 05, page:13 PDF 3049k",https://www.pharmapendium.com/browse/fda/Deferiprone/854bdd01efb0b088e3fe28b227c9037b?reference=13,2011.0,CN1C=CC(=O)C(O)=C1C
Desipramine Hydrochloride,CNCCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,Hepatitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Label 014399/S-063, page:9 PDF 321k",https://www.pharmapendium.com/browse/fda/Desipramine Hydrochloride/3ac94c9b28e9866d08159a62f2f03f88?reference=9,2006.0,CNCCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2
Desloratadine,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 177k",https://www.pharmapendium.com/browse/ema/Desloratadine/20dc7d0f8bfb88c578de16f508dbc492?reference=4,2020.0,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1
Dexlansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,Hepatitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022287/S-021, S-022, S-023, page:90 PDF 13440k",https://www.pharmapendium.com/browse/fda/Dexlansoprazole/dbbee940fe4b56dbd694778f9a06c611?reference=90,2016.0,CC1=C(OCC(F)(F)F)C=CN=C1C[S](=O)C1=NC2=CC=CC=C2N1
Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 204592/S-004 Part 02, page:13 PDF 449k",https://www.pharmapendium.com/browse/fda/Diclofenac/14e6f137ad4ea91951440d702014f0d7?reference=13,2014.0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diclofenac Potassium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022165/S-000, page:6 PDF 1056k",https://www.pharmapendium.com/browse/fda/Diclofenac Potassium/bee628ad74512445c9862588c833927f?reference=6,2009.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1N=CNC2=O,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 020154/S-009, S-011, S-020; 020155/S-007, S-016; 020156/S-007, S-016 Part 03, page:50 PDF 6269k",https://www.pharmapendium.com/browse/fda/Didanosine/3845dcdaa5d13fff8e2b1c0f9e0f0b17?reference=50,1991.0,OC[CH]1CC[CH](O1)N1C=NC2=C1N=CNC2=O
Diltiazem Hydrochloride,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,Hepatitis,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Approval Package 019471/S-004 Part 04, page:54 PDF 5335k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/dad6d5f82fbeaf6aab91e8c02471969c?reference=54,1988.0,COC1=CC=C(C=C1)[CH]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[CH]1OC(C)=O
Dimethyl Fumarate,COC(=O)\C=C\C(=O)OC,Hepatitis,Human,-2.380211241711606,Repeated,Oral,"EMA approval document: ANNEX I, page:37 PDF 520k",https://www.pharmapendium.com/browse/ema/Dimethyl Fumarate/c45eff679ff3b619265c0f59c65df213?reference=37,2020.0,COC(=O)\C=C\C(=O)OC
Diphenadione,O=C(C1C(=O)C2=C(C=CC=C2)C1=O)C(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 009751, page:3 PDF 925k",https://www.pharmapendium.com/browse/fda/Diphenadione/3b51608c40615104bcd706db77212608?reference=3,1966.0,O=C(C1C(=O)C2=C(C=CC=C2)C1=O)C(C1=CC=CC=C1)C1=CC=CC=C1
Dofetilide,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,Hepatitis,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020931 Part 02, page:7 PDF 2322k",https://www.pharmapendium.com/browse/fda/Dofetilide/122c168cbd98b270e4aa3cdea993c60b?reference=7,1998.0,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hepatitis,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/772068/2013; EMEA/H/C/002753/0000, page:82 PDF 1031k",https://www.pharmapendium.com/browse/ema/Dolutegravir Sodium/09d6171337e823a2f9a36399c3b91330?reference=82,2013.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Donepezil Hydrochloride,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 022568/S-000, page:7 PDF 940k",https://www.pharmapendium.com/browse/fda/Donepezil Hydrochloride/30602ceb45c3031c10b630c68c395ae5?reference=7,2010.0,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1
Doravirine,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,Hepatitis,Human,-2.0,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/821709/2018; EMEA/H/C/004747/0000, page:102 PDF 3169k",https://www.pharmapendium.com/browse/ema/Doravirine/8a12e628b625ea0b9b5ea66f50386ff5?reference=102,2018.0,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Hepatitis,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022106/S-000 Part 03, page:10 PDF 6054k",https://www.pharmapendium.com/browse/fda/Doripenem/c864eff186d36706041572b08b92a557?reference=10,2007.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Dronedarone Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,Hepatitis,Human,-2.9030899869919438,Repeated,Intramuscular,"EMA approval document: Assessment Report EMEA/H/C/1043/A20/005, page:18 PDF 943k",https://www.pharmapendium.com/browse/ema/Dronedarone Hydrochloride/ac8f06b056b2958a2f0f1a402458ce78?reference=18,2011.0,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Hepatitis,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 321k",https://www.pharmapendium.com/browse/ema/Duloxetine Hydrochloride/1f8b9696645625ae366d365d5f12e600?reference=7,2020.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 021360/S-006, page:60 PDF 4419k",https://www.pharmapendium.com/browse/fda/Efavirenz/ce317f2f01793e8eb8d66f20846f154b?reference=60,2004.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-008 Part 23, page:5 PDF 1147k",https://www.pharmapendium.com/browse/fda/Empagliflozin/f3b739b56adee05bf8c4e8c82cfbf1c5?reference=5,2015.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Enalaprilat,C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,Hepatitis,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Approval Package 019309/S-015, S-017, S-012, S-020, S-021; 018998/S-038, S-034, S-043, S-053; 019558/S-022; 019778/S-016; 019221/S-019, S-017, S-023 Part 01, page:54 PDF 5466k",https://www.pharmapendium.com/browse/fda/Enalaprilat/c1ded210f1e864707ec587e500079284?reference=54,1994.0,C[CH](N[CH](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[CH]1C(O)=O
Encainide,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,Hepatitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 018981/S-001 Part 10, page:42 PDF 4788k",https://www.pharmapendium.com/browse/fda/Encainide/6cba4c684b45d059c4be622543f67c56?reference=42,1989.0,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
Enfuvirtide,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Hepatitis,Human,-1.954242509439325,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 021481/S-000 Part 03, page:15 PDF 1579k",https://www.pharmapendium.com/browse/fda/Enfuvirtide/9c859d46bfd410da3c7c3fe0f16ead14?reference=15,2003.0,CC[CH](C)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](CC1=CNC=N1)NC(=O)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=C(O)C=C1)NC(C)=O)[CH](C)O)[CH](C)CC)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CO)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](C)C(=O)N[CH](CO)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC1=CC=CC=C1)C(N)=O
Entacapone,CCN(CC)C(=O)C(\C#N)=C\C1=CC(=C(O)C(O)=C1)N(=O)=O,Hepatitis,Human,-1.0,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 190k",https://www.pharmapendium.com/browse/ema/Entacapone/95b881b36cfd6684c32a38e0bc38ee50?reference=6,2020.0,CCN(CC)C(=O)C(\C#N)=C\C1=CC(=C(O)C(O)=C1)N(=O)=O
Entecavir,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)C2=C)C(=O)N1,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021797/S-000, page:99 PDF 6640k",https://www.pharmapendium.com/browse/fda/Entecavir/4e8b214a689c08907da074b52f3b58a4?reference=99,2005.0,NC1=NC2=C(N=CN2[CH]2C[CH](O)[CH](CO)C2=C)C(=O)N1
Erythromycin Ethylsuccinate,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2OC(=O)CCC(=O)OCC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C,Hepatitis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 006205/S-034 Part 03, page:6 PDF 364k",https://www.pharmapendium.com/browse/fda/Erythromycin Ethylsuccinate/bdf04bcb268ada18ca166a2d0fb1d20c?reference=6,2018.0,[H][C]1(C[C](C)(OC)[CH](O)[CH](C)O1)O[CH]1[CH](C)[CH](O[C]2([H])O[CH](C)C[CH]([CH]2OC(=O)CCC(=O)OCC)N(C)C)[C](C)(O)C[CH](C)C(=O)[CH](C)[CH](O)[C](C)(O)[CH](CC)OC(=O)[CH]1C
Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022416/S-000 Part 34, page:10 PDF 3014k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/e5a4ac2fa77cc23999e430ea1c6060ad?reference=10,2013.0,CC(=O)O[CH]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2
Esomeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)[S@@](=O)CC1=NC=C(C)C(OC)=C1C,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 021153/S-025, page:19 PDF 386k",https://www.pharmapendium.com/browse/fda/Esomeprazole Magnesium/4f3362a3b4ca998a2a6866278a897c51?reference=19,2006.0,COC1=CC=C2[N-]C(=NC2=C1)[S](=O)CC1=NC=C(C)C(OC)=C1C
Esomeprazole Sodium,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 021689/S-007, page:9 PDF 284k",https://www.pharmapendium.com/browse/fda/Esomeprazole Sodium/1c22435c698e9787f474311d5feda16d?reference=9,2006.0,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1
Eszopiclone,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1,Hepatitis,Human,-0.3010299956639812,Repeated,Oral,Reference from PharmaPendium Published Toxicity: eszopiclone_cia-2-313   ---   JOURNAL:Clinical Interventions in Aging   PAGES:313   VOLUME:2,,2007.0,CN1CCN(CC1)C(=O)O[CH]1N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Hepatitis,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 06, page:35 PDF 4880k",https://www.pharmapendium.com/browse/fda/Etodolac/c688b5771656ff786492cf1489a4c479?reference=35,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,Hepatitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022187/S-000 Part 02, page:31 PDF 6254k",https://www.pharmapendium.com/browse/fda/Etravirine/23cba3104661ccebce18224813c53489?reference=31,2008.0,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
Etretinate,CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C(C)=C(OC)C=C1C,Hepatitis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019369/S-000, page:13 PDF 4059k",https://www.pharmapendium.com/browse/fda/Etretinate/4c025033beb9f3519d74d667b534ae21?reference=13,1986.0,CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C(C)=C(OC)C=C1C
Everolimus,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatitis,Human,-1.0,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 2287k",https://www.pharmapendium.com/browse/ema/Everolimus/fb8df52a4768e5effd2dd12599ea35e2?reference=17,2020.0,CO[CH]1C[CH](CC[CH]1OCCO)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 021445/S-013, page:14 PDF 429k",https://www.pharmapendium.com/browse/fda/Ezetimibe/14e08036769a34cbfa47a8d80e04d720?reference=14,2006.0,O[CH](CC[CH]1[CH](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022345/S-000 Part 09, page:21 PDF 798k",https://www.pharmapendium.com/browse/fda/Ezogabine/32ffc5ac0f220009d9a5886e136f3359?reference=21,2011.0,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Famotidine,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020325/S-015, page:53 PDF 7378k",https://www.pharmapendium.com/browse/fda/Famotidine/5fa81e4ff6a2de8756c46a0ad36748f1?reference=53,2002.0,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Hepatitis,Human,-2.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:68 PDF 554k",https://www.pharmapendium.com/browse/ema/Febuxostat/90530b38818991c7a21225414abfe220?reference=68,2020.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Felbamate,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,Hepatitis,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Approval Package 020189 Part 01, page:52 PDF 6000k",https://www.pharmapendium.com/browse/fda/Felbamate/6b741dc0ebc3743f785ccb22bfa28113?reference=52,1993.0,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019304 Part 03, page:54 PDF 7698k",https://www.pharmapendium.com/browse/fda/Fenofibrate/7c467e5c47086a300ef271deadab1c7d?reference=54,1993.0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Fenofibric Acid,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O,Hepatitis,Human,-2.0211892990699383,Repeated,Oral,"FDA approval package document: Label 022418/S-000, page:6 PDF 1181k",https://www.pharmapendium.com/browse/fda/Fenofibric Acid/2f262e6a8aa1c940b43c4ff43251fd55?reference=6,2009.0,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
Fenoprofen Calcium,CC(C([O-])=O)C1=CC=CC(OC2=CC=CC=C2)=C1,Hepatitis,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Approval Package 017710; 017604/S-018, page:26 PDF 2632k",https://www.pharmapendium.com/browse/fda/Fenoprofen Calcium/bc12048541c8f2bf0029ac4ce060b3da?reference=26,1977.0,CC(C([O-])=O)C1=CC=CC(OC2=CC=CC=C2)=C1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:24 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=24,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 08, page:48 PDF 1113k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/972ed03239ccc918de6c168481c7e6ec?reference=48,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hepatitis,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Approval Package 019949/S-003, S-012, S-015, S-016, S-017, S-019; 019950/S-004, S-016, S-018, S-021, S-022; 020090/S-002, S-005; 020322/S-001 Part 12, page:19 PDF 4884k",https://www.pharmapendium.com/browse/fda/Fluconazole/c519065d13ec93e02dbaec3acc0fc923?reference=19,1990.0,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Hepatitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 018936, page:75 PDF 2324k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/1e127e48c2431c4d9847a70614888a10?reference=75,1994.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Flurbiprofen,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 018766/S-013, page:11 PDF 339k",https://www.pharmapendium.com/browse/fda/Flurbiprofen/42077615ee502ab6ea0ace4341e5e783?reference=11,2006.0,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Fluticasone Furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Hepatitis,Human,-2.0,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 205625/S-005, page:13 PDF 2832k",https://www.pharmapendium.com/browse/fda/Fluticasone Furoate/e98d45bae3e06a87ef20f5c6a77044d6?reference=13,2018.0,[H][C]12C[CH](C)[C](OC(=O)C3=CC=CO3)(C(=O)SCF)[C]1(C)C[CH](O)[C]1(F)[C]2([H])C[CH](F)C2=CC(=O)C=C[C]12C
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 021192/S-019 Part 01, page:16 PDF 804k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/912bcb0c04151b62b35994f63183a4d8?reference=16,2012.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Fosamprenavir Calcium,CC(C)CN(C[C@@H](OP([O-])([O-])=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hepatitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022116/S-000, page:24 PDF 2940k",https://www.pharmapendium.com/browse/fda/Fosamprenavir Calcium/7ae27e54d942bad779f7bebdaf24714e?reference=24,2007.0,CC(C)CN(C[CH](OP([O-])([O-])=O)[CH](CC1=CC=CC=C1)NC(=O)O[CH]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
Fosinopril Sodium,CCC(=O)O[C@@H](O[P@@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C([O-])=O)C1CCCCC1)C(C)C,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019915/S-009, S-013, S-017, S-021 Part 16, page:6 PDF 8347k",https://www.pharmapendium.com/browse/fda/Fosinopril Sodium/007f5e5c421330f2f7ec870f97409a9b?reference=6,1991.0,CCC(=O)O[CH](O[P](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[CH](C[CH]1C([O-])=O)C1CCCCC1)C(C)C
Fosphenytoin Sodium,[O-]P([O-])(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-1.0791812460476249,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020450/S-003 Part 05, page:17 PDF 544k",https://www.pharmapendium.com/browse/fda/Fosphenytoin Sodium/dac2730e2e50824f308e29c136ec363c?reference=17,2017.0,[O-]P([O-])(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
Fulvestrant,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=C2C=CC(O)=C1,Hepatitis,Human,-2.3979400086720375,Repeated,Intramuscular,"FDA approval package document: Label 210326/S-000, page:24 PDF 2487k",https://www.pharmapendium.com/browse/fda/Fulvestrant/7a132b12570105c3fb178511d05756fd?reference=24,2019.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])[CH](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=C2C=CC(O)=C1
Gabapentin Enacarbil,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(O)=O,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022399/S-000 Part 03, page:48 PDF 6981k",https://www.pharmapendium.com/browse/fda/Gabapentin Enacarbil/e88b89812bbb2c53c47b7c13771f688c?reference=48,2010.0,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(O)=O
Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,Hepatitis,Human,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 020460/S-005 Part 01, page:39 PDF 5337k",https://www.pharmapendium.com/browse/fda/Ganciclovir/af8b89aafda27afd4ca3e4f3b3ba71ff?reference=39,1994.0,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Ganciclovir Sodium,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1,Hepatitis,Human,-1.0,Repeated,Intravenous,"FDA approval package document: Label 019661/S-030, page:21 PDF 690k",https://www.pharmapendium.com/browse/fda/Ganciclovir Sodium/0078e0911648eae74c95fa905199c725?reference=21,2006.0,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1
Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral/intravenous,"FDA approval package document: Other Important Information from FDA 021062/S-000; 021061/S-000; 021678/S-000, page:36 PDF 644k",https://www.pharmapendium.com/browse/fda/Gatifloxacin/d34979a5a28a5b869c8406102ca114ba?reference=36,2006.0,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1
Gefitinib,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2,Hepatitis,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 311k",https://www.pharmapendium.com/browse/ema/Gefitinib/20d5f23f58100a5577a39e215510e76c?reference=4,2019.0,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2
Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,Hepatitis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Label 020496/S-015, page:10 PDF 279k",https://www.pharmapendium.com/browse/fda/Glimepiride/78c66922e53dc9a8e6ff87e31f73c73f?reference=10,2005.0,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[CH]2CC[CH](C)CC2)C1=O
Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 020418 Part 01, page:19 PDF 5445k",https://www.pharmapendium.com/browse/fda/Ibuprofen/4768e9343291bb3125cc346a426033be?reference=19,1994.0,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Idebenone,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Hepatitis,Human,-0.8450980400142568,Repeated,Oral,"EMA approval document: Assessment Report EMA/480039/2015; EMEA/H/C/003834/0000, page:75 PDF 3612k",https://www.pharmapendium.com/browse/ema/Idebenone/c4b8a771f3c8595867bf59231c34f0c1?reference=75,2015.0,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Indomethacin Sodium-0051   ---   JOURNAL:British Medical Journal   PAGES:155   VOLUME:3,,1967.0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 363k",https://www.pharmapendium.com/browse/ema/Irbesartan/6896a9b4513aca35b339ac0ccda3b859?reference=17,2008.0,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Isotretinoin,CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C\C(O)=O,Hepatitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 075945/S-011 Part 01, page:7 PDF 403k",https://www.pharmapendium.com/browse/fda/Isotretinoin/fa4c756e8d93598894e25e874dc246f1?reference=7,2007.0,CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C\C(O)=O
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Hepatitis,Human,-2.6020599913279625,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020966, page:78 PDF 2870k",https://www.pharmapendium.com/browse/fda/Itraconazole/e816200206ea1ca7ddfdaba8985ae24d?reference=78,1998.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:16 PDF 553k",https://www.pharmapendium.com/browse/ema/Ketoconazole/8d2315e4697688e9c94ee9b957e597c1?reference=16,2020.0,[H][C]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019816/S-001, S-002 Part 09, page:70 PDF 4729k",https://www.pharmapendium.com/browse/fda/Ketoprofen/7c397d32cb867f8f0414b6db39cc368c?reference=70,1993.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Label 022253/S-000, page:10 PDF 500k",https://www.pharmapendium.com/browse/fda/Lacosamide/f9396447754a41b64b4f6ca20e26d735?reference=10,2008.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 021003, page:19 PDF 1974k",https://www.pharmapendium.com/browse/fda/Lamivudine/1be670383e63d410d203fedaccf063fd?reference=19,1998.0,NC1=NC(=O)N(C=C1)[CH]1CS[CH](CO)O1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 022115/S-006 Part 02, page:20 PDF 450k",https://www.pharmapendium.com/browse/fda/Lamotrigine/171f116ef046ea14bf851c3870b254e4?reference=20,2011.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Hepatitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020406 Part 02, page:38 PDF 7458k",https://www.pharmapendium.com/browse/fda/Lansoprazole/80496e9e6a5353864119981da10de3da?reference=38,1995.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Lasofoxifene,OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 474k",https://www.pharmapendium.com/browse/ema/Lasofoxifene/4a30d26487d86d298e55209f18660544?reference=7,2013.0,OC1=CC=C2[CH]([CH](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 479k",https://www.pharmapendium.com/browse/ema/Leflunomide/143ff05cfedd6e28c7e1a3db69e310f5?reference=12,2018.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:37 PDF 659k",https://www.pharmapendium.com/browse/ema/Lenalidomide/085a38d0a6c5475c2831f18710affde9?reference=37,2020.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,Hepatitis,Human,-3.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 306k",https://www.pharmapendium.com/browse/ema/Levetiracetam/9874c62cce3ca8764edf55cf95c560fb?reference=10,2020.0,CC[CH](N1CCCC1=O)C(N)=O
Levocetirizine Dihydrochloride,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 022157/S-000, page:4 PDF 778k",https://www.pharmapendium.com/browse/fda/Levocetirizine Dihydrochloride/2feece153eedef4c8a9b0aaaddd0c2ce?reference=4,2010.0,OC(=O)COCCN1CCN(CC1)[CH](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatitis,Human,-2.6989700043360187,Repeated,Intravenous,"FDA approval package document: Summary Review 020634/S-061; 020635/S-067, page:10 PDF 2859k",https://www.pharmapendium.com/browse/fda/Levofloxacin/16b9b5d9bfd7da00d32f37eefca9c03b?reference=10,2012.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Levonorgestrel,[H][C@]12CCC(=O)C=C1CC[C@]1([H])[C@]2([H])CC[C@@]2(CC)[C@@]1([H])CC[C@@]2(O)C#C,Hepatitis,Human,-1.9294189257142926,Repeated,Implant,"FDA approval package document: Approval Package 019897/S-001, S-002, S-003, S-004 Part 02, page:47 PDF 4819k",https://www.pharmapendium.com/browse/fda/Levonorgestrel/27c6e5fb09c2d813e4026286d188c88f?reference=47,1990.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]2([H])CC[C]2(CC)[C]1([H])CC[C]2(O)C#C
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hepatitis,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Approval Package 020632/S-004 Part 01, page:57 PDF 9790k",https://www.pharmapendium.com/browse/fda/Liraglutide/393afd11d3ad0ccc504807db3ce07b6e?reference=57,2017.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lisinopril,[H][C@]1(CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(O)=O,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019777/S-007, S-010, S-014, S-016, S-019, S-021, S-022, S-023, S-024, S-025; 019888/S-007, S-009, S-014, S-021; 019558 Part 19, page:6 PDF 1299k",https://www.pharmapendium.com/browse/fda/Lisinopril/45a3cc5ad12dbaca25c0f68924996ac1?reference=6,1988.0,[H][C]1(CCCN1C(=O)[CH](CCCCN)N[CH](CCC1=CC=CC=C1)C(O)=O)C(O)=O
Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 019658, page:26 PDF 1361k",https://www.pharmapendium.com/browse/fda/Loratadine/ac2dfbec92472bd95fb933301a111f38?reference=26,1995.0,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
Lorcaserin Hydrochloride,C[C@H]1CNCCC2=CC=C(Cl)C=C12,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022529/S-000 Part 03, page:5 PDF 637k",https://www.pharmapendium.com/browse/fda/Lorcaserin Hydrochloride/6fe74588188e0b91f4691d843e3f75bc?reference=5,2012.0,C[CH]1CNCCC2=CC=C(Cl)C=C12
Losartan Potassium,CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Hepatitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Label 020386/S-045, page:14 PDF 338k",https://www.pharmapendium.com/browse/fda/Losartan Potassium/7967a96ba41a06ee08580286dafde840?reference=14,2005.0,CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019643/S-008, S-012, S-028, S-032, S-033, S-035, S-036, S-037, S-041, S-034, S-009, S-018, S-039, S-040, S-042 Part 11, page:50 PDF 5264k",https://www.pharmapendium.com/browse/fda/Lovastatin/95f4d825554551efe2761d8826963afb?reference=50,1990.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)[CH](C)CC
Loxapine Hydrochloride,CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Label 017525/S-051; 017658/S-038; 018039/S-024, page:6 PDF 325k",https://www.pharmapendium.com/browse/fda/Loxapine Hydrochloride/5891388147ae5ecbac6dabcb4b794667?reference=6,2017.0,CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022128/S-000, page:42 PDF 8317k",https://www.pharmapendium.com/browse/fda/Maraviroc/e100e3226906927d8e7a780313319af6?reference=42,2007.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Mefenamic Acid,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 015034/S-032, page:8 PDF 827k",https://www.pharmapendium.com/browse/fda/Mefenamic Acid/bcd696f706f5701412ad5bbb95fb4620?reference=8,1998.0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207233/S-000 Part 04, page:42 PDF 9738k",https://www.pharmapendium.com/browse/fda/Meloxicam/0caf0c63e10542b81af2c271442ab2d4?reference=42,2015.0,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Memantine Hydrochloride,[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 391k",https://www.pharmapendium.com/browse/ema/Memantine Hydrochloride/a6604340fe241b89faeb3219a48bb2bf?reference=5,2019.0,[H][C]12C[C]3(C)C[C](C)(C1)C[C](N)(C2)C3
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Hepatitis,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022301/S-000, page:6 PDF 882k",https://www.pharmapendium.com/browse/fda/Mesalamine/5851436c18a73308bd7a26b78b8b3870?reference=6,2008.0,NC1=CC(C(O)=O)=C(O)C=C1
Metformin Hydrochloride,CN(C)C(=N)NC(N)=N,Hepatitis,Human,-2.929418925714293,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020357 Part 03, page:8 PDF 1951k",https://www.pharmapendium.com/browse/fda/Metformin Hydrochloride/031d8bc21f6a622b853c27a3ef611e56?reference=8,,CN(C)C(=N)NC(N)=N
Methimazole,CN1C=CNC1=S,Hepatitis,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Label 007517/S-022, page:3 PDF 480k",https://www.pharmapendium.com/browse/fda/Methimazole/d0109b41ed065fe52623158b8c92a5d5?reference=3,2009.0,CN1C=CNC1=S
Mexiletine Hydrochloride,CC(N)COC1=C(C)C=CC=C1C,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/831802/2018; EMEA/H/C/004584/0000, page:116 PDF 3055k",https://www.pharmapendium.com/browse/ema/Mexiletine Hydrochloride/0339e2432f1279187517a7d5ce5d49a6?reference=116,2018.0,CC(N)COC1=C(C)C=CC=C1C
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatitis,Human,-2.1760912590556813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000 Part 04, page:7 PDF 7162k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/bed36c7c52cf41ed159f180586049913?reference=7,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Milnacipran Hydrochloride,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Label 022256/S-000, page:12 PDF 480k",https://www.pharmapendium.com/browse/fda/Milnacipran Hydrochloride/d90d83e340a7ba39f84558eb89b4994a?reference=12,2009.0,CCN(CC)C(=O)[C]1(C[CH]1CN)C1=CC=CC=C1
Minocycline Hydrochloride,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Hepatitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 050808/S-014 Part 01, page:11 PDF 303k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/31f5da0487309d3b69b91cef30181e69?reference=11,2011.0,[H][C]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Mometasone Furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Hepatitis,Human,-2.6020599913279625,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 021067/S-000 Part 02, page:87 PDF 5587k",https://www.pharmapendium.com/browse/fda/Mometasone Furoate/2fb64796327da0fe3482516707a6d7cb?reference=87,2005.0,[H][C]12C[CH](C)[C](OC(=O)C3=CC=CO3)(C(=O)CCl)[C]1(C)C[CH](O)[C]1(Cl)[C]2([H])CCC2=CC(=O)C=C[C]12C
Moricizine Hydrochloride,CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN3CCOCC3)C2=C1,Hepatitis,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Approval Package 019753 Part 01, page:20 PDF 6242k",https://www.pharmapendium.com/browse/fda/Moricizine Hydrochloride/c3f0b79bd6f99d950b0cee99b32b827b?reference=20,1990.0,CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN3CCOCC3)C2=C1
Moxifloxacin Hydrochloride,[H][C@@]12CCCN[C@]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021085/S-010; 021334/S-000, page:42 PDF 1745k",https://www.pharmapendium.com/browse/fda/Moxifloxacin Hydrochloride/1662ebfc721a7169705e8138fce783a5?reference=42,2001.0,[H][C]12CCCN[C]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1,Hepatitis,Human,-3.6989700043360187,Repeated,Multiple,"FDA approval package document: Medical/Clinical Review 050722/S-005; 050723/S-005; 050758/S-004; 050759/S-006, page:35 PDF 1890k",https://www.pharmapendium.com/browse/fda/Mycophenolate Mofetil/6a37819bb169f4f2a7bf971cb6cb5007?reference=35,2000.0,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
Nedocromil Sodium,CCCC1=C2OC(=CC(=O)C2=CC2=C1N(CC)C(=CC2=O)C([O-])=O)C([O-])=O,Hepatitis,Human,-1.146128035678238,Repeated,Inhalation,"FDA approval package document: Approval Package 019660/S-003, S-010, S-015 Part 05, page:41 PDF 7331k",https://www.pharmapendium.com/browse/fda/Nedocromil Sodium/145e52545d7a9387e1516f38bb56ff2b?reference=41,1993.0,CCCC1=C2OC(=CC(=O)C2=CC2=C1N(CC)C(=CC2=O)C([O-])=O)C([O-])=O
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 742k",https://www.pharmapendium.com/browse/ema/Nevirapine/f3292fccf515eca05ba0b31687fcd313?reference=17,2020.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,Hepatitis,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Approval Package 020198 Part 02, page:6 PDF 7366k",https://www.pharmapendium.com/browse/fda/Nifedipine/2be7688aba1be2659370e4a8c8a097dd?reference=6,1995.0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 022068/S-000, page:10 PDF 326k",https://www.pharmapendium.com/browse/fda/Nilotinib Hydrochloride Monohydrate/f322685b508d762bb135f8a217a6a292?reference=10,2007.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nilutamide,CC1(C)NC(=O)N(C2=CC=C(C(=C2)C(F)(F)F)N(=O)=O)C1=O,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical Officer Review 020169, page:14 PDF 591k",https://www.pharmapendium.com/browse/fda/Nilutamide/fc6a923cc670cfaa1045fa4ebf0f27f4?reference=14,1995.0,CC1(C)NC(=O)N(C2=CC=C(C(=C2)C(F)(F)F)N(=O)=O)C1=O
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OC(C)C,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Pharmacology Review 018869, page:5 PDF 430k",https://www.pharmapendium.com/browse/fda/Nimodipine/e88cab4c81511472255ec25e568cc6d0?reference=5,,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OC(C)C
"Nitrofurantoin, Macrocrystalline",O=C1CN(C(=O)N1)\N=C\C1=CC=C(O1)N(=O)=O,Hepatitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 016620/S-064, page:29 PDF 2554k","https://www.pharmapendium.com/browse/fda/Nitrofurantoin, Macrocrystalline/87b6846f59ea68c204bf40dd016affea?reference=29",2003.0,O=C1CN(C(=O)N1)\N=C\C1=CC=C(O1)N(=O)=O
Nizatidine,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Printed Labeling 021494/S-000, page:8 PDF 972k",https://www.pharmapendium.com/browse/fda/Nizatidine/48bb51b3c36a8fa9cb390213dfb5f04b?reference=8,2004.0,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O
Nomifensine,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 018224 Part 02, page:36 PDF 3804k",https://www.pharmapendium.com/browse/fda/Nomifensine/e446c3328772dca77a06d98942f108c6?reference=36,1984.0,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2
Norfloxacin,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 019384/S-007, S-009, S-011, S-012, S-013, S-014, S-015, S-020, S-021, S-022, S-023, S-028 Part 07, page:17 PDF 2318k",https://www.pharmapendium.com/browse/fda/Norfloxacin/0fd8857ed6f695e0cb609135b405422c?reference=17,1986.0,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
Ofloxacin,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 019735/S-002, S-005, S-006, S-017, S-024, S-035, S-041, S-042; 020087/S-017 Part 14, page:29 PDF 7211k",https://www.pharmapendium.com/browse/fda/Ofloxacin/2c51783bd554e63801f2040c23dc2f9b?reference=29,1990.0,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 385k",https://www.pharmapendium.com/browse/ema/Olanzapine/4a9fc53882e2467a371b65b3f2d8c45f?reference=6,2020.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019810/S-002, S-007, S-036, S-037, S-009, S-010, S-022, S-035, S-019, S-023, S-025, S-033, S-034; 050662/S-010 Part 21, page:48 PDF 6127k",https://www.pharmapendium.com/browse/fda/Omeprazole/1f18354d13e32eec8cbbb691e34fed35?reference=48,1990.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021229/S-000, page:181 PDF 20401k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/42ffe48b5d32d8a231f5c085c007aa78?reference=181,2003.0,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Ondansetron Hydrochloride,CN1C2=C(C(=O)C(CC2)CN2C=CN=C2C)C2=C1C=CC=C2,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020103/S-004; 020007/S-017, S-008, S-007 Part 02, page:10 PDF 8329k",https://www.pharmapendium.com/browse/fda/Ondansetron Hydrochloride/3d5dbcd9b676e055f369348787d5936e?reference=10,1992.0,CN1C2=C(C(=O)C(CC2)CN2C=CN=C2C)C2=C1C=CC=C2
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Hepatitis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 01, page:43 PDF 4480k",https://www.pharmapendium.com/browse/fda/Orlistat/3f97e8190e694a8cb2e2e90a1f1afa61?reference=43,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxaprozin,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018841/S-003, S-001, S-002, S-004, S-005 Part 02, page:38 PDF 11237k",https://www.pharmapendium.com/browse/fda/Oxaprozin/a591ca196a9f82f4f0e7e4359c600b1f?reference=38,1992.0,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Hepatitis,Human,-3.380211241711606,Repeated,Oral,"FDA approval package document: Approval Package 078734/S-000 Part 02, page:5 PDF 4827k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/e640954ff6d039d46590299b60b86f2c?reference=5,2009.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Ozanimod Hydrochloride,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,Hepatitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209899/S-000 Part 04, page:26 PDF 9758k",https://www.pharmapendium.com/browse/fda/Ozanimod Hydrochloride/8b224be2239d5e5f42efec391f71668d?reference=26,2019.0,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[CH](NCCO)C2=CC=C1)C#N
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020987/S-007, page:34 PDF 1373k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/fc792609ea1639d725d409fa83f0f250?reference=34,2002.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Para-Aminosalicylic Sodium,NC1=CC(O)=C(C=C1)C([O-])=O,Hepatitis,Human,-4.176091259055681,Repeated,Oral,"FDA approval package document: Approval Package 006924, page:5 PDF 701k",https://www.pharmapendium.com/browse/fda/Para-Aminosalicylic Sodium/b2f51097a8a69bf801b952d56bf1bdf9?reference=5,,NC1=CC(O)=C(C=C1)C([O-])=O
Paramethadione,CCC1(C)OC(=O)N(C)C1=O,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 006800, page:4 PDF 498k",https://www.pharmapendium.com/browse/fda/Paramethadione/1b0f63c816f4740840862ca0a6bfabf0?reference=4,1949.0,CCC1(C)OC(=O)N(C)C1=O
Parecoxib,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1,Hepatitis,Human,-1.6020599913279623,Repeated,Parenteral,"EMA approval document: ANNEX I, page:11 PDF 591k",https://www.pharmapendium.com/browse/ema/Parecoxib/48cad50f901910b6a3c6dffb4ca8f9db?reference=11,2020.0,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Hepatitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Label 077395 Part 02, page:9 PDF 4432k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/1a8809c0636779bdcb24a97a2b97ae6f?reference=9,2006.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/001141, page:54 PDF 613k",https://www.pharmapendium.com/browse/ema/Pazopanib Hydrochloride/0a109978309581c3085fce67dac7e2fd?reference=54,2010.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Penicillamine,CC(C)(S)[C@H](N)C(O)=O,Hepatitis,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 050491 Part 01, page:9 PDF 5024k",https://www.pharmapendium.com/browse/fda/Penicillamine/f4eac439c72373bbc74fda5c16f8e622?reference=9,1978.0,CC(C)(S)[CH](N)C(O)=O
Phenindione,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1,Hepatitis,Human,-2.6989700043360187,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Phenindione-0035   ---   JOURNAL:Canadian Medical Association Journal   PAGES:1028   VOLUME:77,,1957.0,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1
Phenylbutazone,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis,Human,-2.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Phenylbutazone-0038   ---   JOURNAL:Canadian Medical Association Journal   PAGES:1211   VOLUME:83,,1960.0,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
Phthalylsulfathiazole,OC(=O)C1=C(C=CC=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,Hepatitis,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 005803, page:4 PDF 724k",https://www.pharmapendium.com/browse/fda/Phthalylsulfathiazole/a57b1590fb877088111ee7f494268030?reference=4,1945.0,OC(=O)C1=C(C=CC=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Hepatitis,Human,-1.6532125137753437,Repeated,Oral,"FDA approval package document: Approval Package 021073/S-023, page:21 PDF 4047k",https://www.pharmapendium.com/browse/fda/Pioglitazone Hydrochloride/64d50ed1460da817c37772b2c3682588?reference=21,2004.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Pirfenidone,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,Hepatitis,Human,-3.3807537708039,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022535/S-000 Part 03, page:70 PDF 12104k",https://www.pharmapendium.com/browse/fda/Pirfenidone/b8014a7215fd2de278852a4cfc186ed8?reference=70,2010.0,CC1=CN(C(=O)C=C1)C1=CC=CC=C1
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 022363/S-008, S-009 Part 03, page:7 PDF 696k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/ea6bbc31c7abef908790ac73c5f7e399?reference=7,2012.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Pomalidomide,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"EMA approval document: ANNEX I, page:23 PDF 642k",https://www.pharmapendium.com/browse/ema/Pomalidomide/8672234b6ceff4786a1177dd2551914b?reference=23,2020.0,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Label 205596/S-000 Part 01, page:8 PDF 416k",https://www.pharmapendium.com/browse/fda/Posaconazole/7dbb1a8d689660abb03cc68ca3a7020f?reference=8,2014.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022514/S-000 Part 15, page:4 PDF 472k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/575ae229cbcdb9c8e44d2ea636ec39ce?reference=4,2009.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Pravastatin Sodium,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)OC(=O)[C@@H](C)CC,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-050, page:6 PDF 4062k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/108a6de2bc9734d7224a77deebc2b034?reference=6,2002.0,[H][C]12[CH](C[CH](O)C=C1C=C[CH](C)[CH]2CC[CH](O)C[CH](O)CC([O-])=O)OC(=O)[CH](C)CC
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:70 PDF 334k",https://www.pharmapendium.com/browse/ema/Pregabalin/2b526e960898b50aa2cb94477561fac5?reference=70,2021.0,CC(C)C[CH](CN)CC(O)=O
Proguanil Hydrochloride,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,Hepatitis,Human,-0.7781512503836436,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Ann. Pharmacother.; VOL 32 ISS Oct 1998, P1023-1025, (REF 9)   ---   JOURNAL:Annals of Pharmacotherpy   PAGES:1023   VOLUME:32",,1998.0,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
Propranolol Hydrochloride,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,Hepatitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205410/S-000 Part 06, page:53 PDF 961k",https://www.pharmapendium.com/browse/fda/Propranolol Hydrochloride/a08cb35b9ee04ee93388a535582c2c5b?reference=53,2013.0,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
Propylthiouracil,CCCC1=CC(=O)NC(=S)N1,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 006286, page:3 PDF 442k",https://www.pharmapendium.com/browse/fda/Propylthiouracil/e40f9debb5a51393dd00c4e2e4942067?reference=3,1947.0,CCCC1=CC(=O)NC(=S)N1
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical Officer Review 020973, page:24 PDF 1524k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/8a376a97d1307c2727bbe4bd44ffed8c?reference=24,1998.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 205786/S-000 Part 03, page:16 PDF 1483k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/f6cfe89718508bf3d1a727454e2abd74?reference=16,2013.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Hepatitis,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 019901/S-046, page:5 PDF 315k",https://www.pharmapendium.com/browse/fda/Ramipril/65423e37e6b2eb8bb13b7fd605ec1be6?reference=5,2005.0,[H][C]12CCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021698/S-000, page:119 PDF 7752k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/d649577b6b69cdfb36e83266f39471d9?reference=119,2004.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Hepatitis,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 214787/S-000 Part 03, page:30 PDF 1237k",https://www.pharmapendium.com/browse/fda/Remdesivir/27efae85ef2e8d3460cff7dde5014c8d?reference=30,2020.0,CCC(CC)COC(=O)[CH](C)N[P](=O)(OC[CH]1O[C](C#N)([CH](O)[CH]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Hepatitis,Human,-3.146128035678238,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 511k",https://www.pharmapendium.com/browse/ema/Ribavirin/0f6da39093f1e3353868e51d6fed1035?reference=12,2020.0,NC(=O)C1=NN(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Rifampin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(C)CC1)=C2O,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 050429, page:5 PDF 4018k",https://www.pharmapendium.com/browse/fda/Rifampin/4c395f8c75dbc0cabc0e90e4b0ff0d05?reference=5,1971.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C(\C=N\N1CCN(C)CC1)=C2O
Rilpivirine Hydrochloride,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202022/S-000, page:52 PDF 1064k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/9ced65a4af087352a74203f63a45eb54?reference=52,2011.0,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Hepatitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020599/S-011 Part 01, page:18 PDF 358k",https://www.pharmapendium.com/browse/fda/Riluzole/574e4a8501e51da4f7704c1c56c447b3?reference=18,2006.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Hepatitis,Human,-1.6989700043360187,Repeated,Intramuscular,"FDA approval package document: Label 021346/S-013, page:28 PDF 1117k",https://www.pharmapendium.com/browse/fda/Risperidone/0c7946c7391b69ddee75d111e62bc4b5?reference=28,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020659/S-013; 020680/S-011, page:26 PDF 1907k",https://www.pharmapendium.com/browse/fda/Ritonavir/143054799d45326c3a6bd29a24234e02?reference=26,1998.0,CC(C)[CH](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[CH](C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 01, page:67 PDF 1333k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/bc6e880b062db2c78b661508027015fd?reference=67,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,Hepatitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021042/S-007, S-008, S-010, S-012, S-013, S-014, S-009; 021052/S-004, S-005, S-006, S-007, S-008, S-009 Part 03, page:6 PDF 1391k",https://www.pharmapendium.com/browse/fda/Rofecoxib/46bd8ddadf38ce75517b44260f05c793?reference=6,2001.0,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
Ropinirole Hydrochloride,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020658/S-013 Part 03, page:40 PDF 926k",https://www.pharmapendium.com/browse/fda/Ropinirole Hydrochloride/98fa350a7918770f396cd65478b7bd5d?reference=40,2005.0,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-024 Part 03, page:24 PDF 933k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/fd6f850669161bf26eb7261f0808b3aa?reference=24,2012.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Rufinamide,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,Hepatitis,Human,-3.505149978319906,Repeated,Oral,"FDA approval package document: Label 201367/S-000, page:6 PDF 559k",https://www.pharmapendium.com/browse/fda/Rufinamide/9867e5e7807c991e20317809c7a87510?reference=6,2011.0,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
Saxagliptin Hydrochloride,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)[C@H](N)C(=O)N1[C@@H](C[C@]2([H])C[C@]12[H])C#N,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Assessment Report EMA/302364/2013; EMEA/H/C/xxxx/WS/0295, page:29 PDF 1533k",https://www.pharmapendium.com/browse/ema/Saxagliptin Hydrochloride/5c756af95227a50d80b6503af3874189?reference=29,2013.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)[CH](N)C(=O)N1[CH](C[C]2([H])C[C]12[H])C#N
Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-077 Part 05, page:38 PDF 1867k",https://www.pharmapendium.com/browse/fda/Simvastatin/dcbb2098087431d0b30bf060263ea725?reference=38,2011.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)C(C)(C)CC
Sirolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Administrative documents 021083/S-006 Part 02, page:2 PDF 6529k",https://www.pharmapendium.com/browse/fda/Sirolimus/bd2a7c57272d532e1fd1f00a156779c6?reference=2,2003.0,CO[CH]1C[CH](CC[CH]1O)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Sotorasib,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F,Hepatitis,Human,-2.9822712330395684,Repeated,Oral,"FDA approval package document: Label 214665/S-001, page:5 PDF 805k",https://www.pharmapendium.com/browse/fda/Sotorasib/c5664fac0861ff234e58ece9a54e2869?reference=5,2021.0,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[CH]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F
Stavudine,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,Hepatitis,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 3068k",https://www.pharmapendium.com/browse/ema/Stavudine/6ad9975c57fd1d005f31eb302771e254?reference=9,2020.0,CC1=CN([CH]2O[CH](CO)C=C2)C(=O)NC1=O
Stiripentol,CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1,Hepatitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206709/S-000; 207223/S-000 Part 01, page:173 PDF 2233k",https://www.pharmapendium.com/browse/fda/Stiripentol/2fa86c5ab0867c548d9f0e4245ea5508?reference=173,2018.0,CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1
Strontium Ranelate,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,Hepatitis,Human,-3.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 399k",https://www.pharmapendium.com/browse/ema/Strontium Ranelate/c781cc83ff269f3560db102902636aca?reference=6,2012.0,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O
Sulfadiazine,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1,Hepatitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 040091 Part 02, page:7 PDF 758k",https://www.pharmapendium.com/browse/fda/Sulfadiazine/b8859e7374fb656d7533113f3288475f?reference=7,1996.0,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
Sulfadiazine Sodium,NC1=CC=C(C=C1)S([O-])(=O)=NC1=NC=CC=N1,Hepatitis,Human,0.0,Repeated,Oral/intravenous,"FDA approval package document: Approval Package 005592, page:8 PDF 1250k",https://www.pharmapendium.com/browse/fda/Sulfadiazine Sodium/0234a95d921748014cfac516966959a4?reference=8,1944.0,NC1=CC=C(C=C1)S([O-])(=O)=NC1=NC=CC=N1
Sulfadimethoxine,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1,Hepatitis,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Review 011766 Part 05, page:1 PDF 3038k",https://www.pharmapendium.com/browse/fda/Sulfadimethoxine/129b82170dddeddccb03dd9026a116d9?reference=1,1968.0,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1
Sulfaethidole,CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,Hepatitis,Human,-4.977723605288848,Repeated,Oral,"FDA approval package document: Review 010643, page:5 PDF 890k",https://www.pharmapendium.com/browse/fda/Sulfaethidole/c3b0ac9ec6a84bc2e372c0413dd1ffea?reference=5,,CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1
Sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,Hepatitis,Human,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Review 012715, page:18 PDF 1344k",https://www.pharmapendium.com/browse/fda/Sulfamethoxazole/646d970a7e5f24bb9c573b833683e213?reference=18,1965.0,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
Sulfamethoxypyridazine,COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1,Hepatitis,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 010849, page:18 PDF 5807k",https://www.pharmapendium.com/browse/fda/Sulfamethoxypyridazine/cf86ec5790f7922db98245a1673a0484?reference=18,1968.0,COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1
Sulfasalazine,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Hepatitis,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021243/S-000, page:29 PDF 351k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/d95e9c143487ab782457adcf5f06a0cc?reference=29,2000.0,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
Sulfisoxazole,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,Hepatitis,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 006525, page:42 PDF 5798k",https://www.pharmapendium.com/browse/fda/Sulfisoxazole/780e7b73bfb53f95c637e86fa66c5a8d?reference=42,,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,Hepatitis,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:82 PDF 705k",https://www.pharmapendium.com/browse/ema/Sunitinib/95d35eea3df7c71029f241d18fa5927a?reference=82,2021.0,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C
Suprofen,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018217/S-011, S-009 Part 04, page:13 PDF 4453k",https://www.pharmapendium.com/browse/fda/Suprofen/6988a750d6b13dae943ae44836524507?reference=13,1985.0,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 02, page:30 PDF 7668k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/b5bec82e2e64bde8d0350f73570634d3?reference=30,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hepatitis,Human,-0.47712125471966244,Repeated,Multiple,"FDA approval package document: Medical/Clinical Review 050709/S-000 Part 02, page:8 PDF 1998k",https://www.pharmapendium.com/browse/fda/Tacrolimus/7f919e946ff6a83d35fda82717199ce9?reference=8,1993.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Telavancin Hydrochloride,CCCCCCCCCCNCCN[C@@]1(C)C[C@@H](O[C@@H](C)[C@H]1O)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2OC3=C(Cl)C=C(C=C3)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]4C(=O)N[C@@H]([C@H](O)C5=CC=C(OC1=CC3=C2)C(Cl)=C5)C(=O)N[C@H](C(O)=O)C1=C(C(O)=C(CNCP(O)(O)=O)C(O)=C1)C1=C(O)C=CC4=C1,Hepatitis,Human,-1.0,Repeated,Intravenous,"EMA approval document: ANNEX I, page:8 PDF 989k",https://www.pharmapendium.com/browse/ema/Telavancin Hydrochloride/ec84edef47e5b660ba3b85d5550bbe4f?reference=8,2018.0,CCCCCCCCCCNCCN[C]1(C)C[CH](O[CH](C)[CH]1O)O[CH]1[CH](O)[CH](O)[CH](CO)O[CH]1OC1=C2OC3=C(Cl)C=C(C=C3)[CH](O)[CH](NC(=O)[CH](CC(C)C)NC)C(=O)N[CH](CC(N)=O)C(=O)N[CH]3C(=O)N[CH]4C(=O)N[CH]([CH](O)C5=CC=C(OC1=CC3=C2)C(Cl)=C5)C(=O)N[CH](C(O)=O)C1=C(C(O)=C(CNCP(O)(O)=O)C(O)=C1)C1=C(O)C=CC4=C1
Telbivudine,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022154/S-000 Part 02, page:70 PDF 6048k",https://www.pharmapendium.com/browse/fda/Telbivudine/3503c73eba7bc95acbe717f48fd3a582?reference=70,2009.0,CC1=CN([CH]2C[CH](O)[CH](CO)O2)C(=O)NC1=O
Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: Scientific Discussion, page:19 PDF 853k",https://www.pharmapendium.com/browse/ema/Telithromycin/f955bb877517e24cc0ac303e4d450ed6?reference=19,2001.0,[H][C]12[CH](C)C(=O)[CH](C)C[C](C)(OC)[CH](O[CH]3O[CH](C)C[CH]([CH]3O)N(C)C)[CH](C)C(=O)[CH](C)C(=O)O[CH](CC)[C]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatitis,Human,-0.8450980400142568,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:58 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=58,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,Hepatitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020785/S-000, page:126 PDF 9333k",https://www.pharmapendium.com/browse/fda/Thalidomide/4c85e5877c2ee1981460a1a712016473?reference=126,1998.0,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1
Ticlopidine Hydrochloride,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,Hepatitis,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019979/S-009 Part 01, page:15 PDF 4844k",https://www.pharmapendium.com/browse/fda/Ticlopidine Hydrochloride/4bc0829b6ee4b0df83fd124d16f973f9?reference=15,1991.0,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
Tinidazole,CCS(=O)(=O)CCN1C(C)=NC=C1N(=O)=O,Hepatitis,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021618/S-000; 021681/S-000; 021682/S-000 Part 01, page:30 PDF 1565k",https://www.pharmapendium.com/browse/fda/Tinidazole/ef8074e8d0653227e6b5ac94398a11e1?reference=30,2004.0,CCS(=O)(=O)CCN1C(C)=NC=C1N(=O)=O
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Hepatitis,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 021822/S-000, page:8 PDF 985k",https://www.pharmapendium.com/browse/fda/Tipranavir/affbc847ec87ab7057d93cd9f57b983b?reference=8,2010.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Tizanidine Hydrochloride,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Hepatitis,Human,-1.5563025007672873,Repeated,Oral,"FDA approval package document: Medical Officer Review 020397, page:10 PDF 728k",https://www.pharmapendium.com/browse/fda/Tizanidine Hydrochloride/fadd8cf1a4115fd6ce090d88629487af?reference=10,1994.0,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Tocainide Hydrochloride,CC(N)C(=O)NC1=C(C)C=CC=C1C,Hepatitis,Human,-2.9030899869919438,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Lorcainide618.full   ---   DOI:10.1378/chest.88.4.618   JOURNAL:Chest   PAGES:618   VOLUME:88,http://dx.doi.org/10.1378/chest.88.4.618,1985.0,CC(N)C(=O)NC1=C(C)C=CC=C1C
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Hepatitis,Human,-1.954242509439325,Repeated,Oral,"EMA approval document: Assessment Report EMA/154879/2015; EMEA/H/C/002788/0000, page:91 PDF 2217k",https://www.pharmapendium.com/browse/ema/Tolvaptan/71bcaa292b00cbf2fcf27b82d36ca6ae?reference=91,2015.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Hepatitis,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020844/S-001 Part 04, page:23 PDF 844k",https://www.pharmapendium.com/browse/fda/Topiramate/965314db23724c21d6f68ab9d000ea35?reference=23,1999.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Tramadol Hydrochloride,COC1=CC(=CC=C1)[C@]1(O)CCCC[C@H]1CN(C)C,Hepatitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 075977/S-000, page:13 PDF 8482k",https://www.pharmapendium.com/browse/fda/Tramadol Hydrochloride/62935be7f1cd98a1debb9dca1f33e136?reference=13,2002.0,COC1=CC(=CC=C1)[C]1(O)CCCC[CH]1CN(C)C
Trandolapril,[H][C@]12CCCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020528/S-001 Part 02, page:14 PDF 1012k",https://www.pharmapendium.com/browse/fda/Trandolapril/281895f55f444bcb4024286951c134cb?reference=14,1996.0,[H][C]12CCCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Trimethadione,CN1C(=O)OC(C)(C)C1=O,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Trimethadione-0029   ---   JOURNAL:Canadian Medical Association Journal   PAGES:200   VOLUME:85,,1961.0,CN1C(=O)OC(C)(C)C1=O
Upadacitinib,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F,Hepatitis,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 211675/S-000 Part 05, page:7 PDF 751k",https://www.pharmapendium.com/browse/fda/Upadacitinib/3c6ce3b9a18f071202ec95401c9d4de8?reference=7,2019.0,CC[CH]1CN(C[CH]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
Valdecoxib,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C1=CC=CC=C1,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021341/S-000 Part 03, page:75 PDF 3669k",https://www.pharmapendium.com/browse/fda/Valdecoxib/393cae7dcde505c5b787ef005d70b3c6?reference=75,2001.0,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C1=CC=CC=C1
Valganciclovir Hydrochloride,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1N=C(N)NC2=O,Hepatitis,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Approval Package 021304/S-001, page:171 PDF 9958k",https://www.pharmapendium.com/browse/fda/Valganciclovir Hydrochloride/e1a774ff88ed603671c561aabe592add?reference=171,2003.0,CC(C)[CH](N)C(=O)OCC(CO)OCN1C=NC2=C1N=C(N)NC2=O
Valproic Acid,CCCC(CCC)C(O)=O,Hepatitis,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Label 022152/S-000, page:7 PDF 2900k",https://www.pharmapendium.com/browse/fda/Valproic Acid/88c66476b9da5a618fafc46021c6d832?reference=7,2007.0,CCCC(CCC)C(O)=O
Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)[C@@H](C(C)C)C(O)=O,Hepatitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 021283/S-024 Part 02, page:27 PDF 9538k",https://www.pharmapendium.com/browse/fda/Valsartan/5c4d31873f9f24770896e111d48b0fe1?reference=27,2007.0,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)[CH](C(C)C)C(O)=O
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Hepatitis,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Approval Package 020151; 020527 Part 02, page:91 PDF 7315k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/9f634a28eacbefbc406fe3e419e7a3a0?reference=91,1993.0,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Vigabatrin,NC(CCC(O)=O)C=C,Hepatitis,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 07, page:67 PDF 6166k",https://www.pharmapendium.com/browse/fda/Vigabatrin/efee566c5d5bc0813df5f24a38b6e661?reference=67,2009.0,NC(CCC(O)=O)C=C
Vildagliptin,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)NCC(=O)N1CCC[C@@H]1C#N,Hepatitis,Human,-2.0,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 534k",https://www.pharmapendium.com/browse/ema/Vildagliptin/175999fa7b38ec4130f628d7f44e8908?reference=4,2020.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)NCC(=O)N1CCC[CH]1C#N
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hepatitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021266/S-000; 021267/S-000 Part 04, page:32 PDF 1582k",https://www.pharmapendium.com/browse/fda/Voriconazole/b91def2fd3ba7fba9e4703146e866659?reference=32,2001.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Hepatitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 020547/S-029, page:18 PDF 1194k",https://www.pharmapendium.com/browse/fda/Zafirlukast/244ecd1e992ff73be2fed108af9f0eb5?reference=18,2009.0,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Hepatitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 020199 Part 01, page:20 PDF 3966k",https://www.pharmapendium.com/browse/fda/Zalcitabine/7516791f2c2ebfd4e1d211931a39b97b?reference=20,1992.0,NC1=NC(=O)N(C=C1)[CH]1CC[CH](CO)O1
Zanamivir,[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Hepatitis,Human,-2.7781512503836434,Repeated,Intravenous,"EMA approval document: Public Assessment Report EMA/CHMP/851480/2018; EMEA/H/C/004102/0000, page:107 PDF 2375k",https://www.pharmapendium.com/browse/ema/Zanamivir/0160f7132f67bf85b6bfb2d976c2fd6f?reference=107,2019.0,[H][C]1(OC(=C[CH](NC(N)=N)[CH]1NC(C)=O)C(O)=O)[CH](O)[CH](O)CO
Ziconotide,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O,Hepatitis,Human,-0.6020599913279624,Repeated,Intrathecal,"FDA approval package document: Medical/Clinical Review 021060/S-000, page:77 PDF 13268k",https://www.pharmapendium.com/browse/fda/Ziconotide/b6a6f3e30586d594a8d3aeb7d55ea80e?reference=77,2004.0,CSCC[CH]1NC(=O)[CH](CC(C)C)NC(=O)[CH](CCCNC(N)=N)NC(=O)[CH](CO)NC(=O)[CH]2CSSC[CH]3NC(=O)[CH](CO)NC(=O)CNC(=O)[CH](NC(=O)[CH](CSSC[CH](N)C(=O)N[CH](CCCCN)C(=O)NCC(=O)N[CH](CCCCN)C(=O)NCC(=O)N[CH](C)C(=O)N[CH](CCCCN)C(=O)N2)NC(=O)[CH](CSSC[CH](NC(=O)[CH](CCCCN)NC(=O)CNC(=O)[CH](CO)NC(=O)[CH](CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)[CH](CC(O)=O)NC(=O)[CH](CC2=CC=C(O)C=C2)NC1=O)[CH](C)O
Zidovudine,CC1=CN([C@H]2C[C@H](N=N#N)[C@@H](CO)O2)C(=O)NC1=O,Hepatitis,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022294/S-000, page:10 PDF 1706k",https://www.pharmapendium.com/browse/fda/Zidovudine/70ff07f13b40ebc73f6eb329d66c9777?reference=10,2009.0,CC1=CN([CH]2C[CH](N=N#N)[CH](CO)O2)C(=O)NC1=O
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Hepatitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020471/S-009, page:10 PDF 1570k",https://www.pharmapendium.com/browse/fda/Zileuton/b0a168b63e38558264aee455efee2c0a?reference=10,2002.0,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Ziprasidone Hydrochloride,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12,Hepatitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020825/S-021; 020919/S-012, page:29 PDF 4127k",https://www.pharmapendium.com/browse/fda/Ziprasidone Hydrochloride/7d8ee6172d21b6fea5f9a04021d4e70e?reference=29,2007.0,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12
Zomepirac,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1,Hepatitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018236/S-008, S-009, S-015, S-017, S-018, S-024 Part 01, page:35 PDF 4981k",https://www.pharmapendium.com/browse/fda/Zomepirac/10da7357d7cbbfd7b3b016170e4e470c?reference=35,1983.0,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
